• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Friday, November 20, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Adaptive Lenalidomide Intensification Evaluated Following CyBorD Induction in Multiple Myeloma

by
November 8, 2026
in Health
Reading Time: 5 mins read
0
Adaptive Lenalidomide Intensification Evaluated Following CyBorD Induction in Multiple Myeloma

Adaptive Lenalidomide Intensification Evaluated Following CyBorD Induction in Multiple Myeloma

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

A prospective multicenter clinical trial investigating a response-adapted intensification strategy for transplant-eligible patients with newly diagnosed multiple myeloma found that adding second-line lenalidomide and dexamethasone after cyclophosphamide, bortezomib, and dexamethasone induction did not improve complete response rates compared with historical benchmarks. The study, designated the PIANO trial, enrolled 63 evaluable patients across 10 centers in Japan to assess whether individuals experiencing an insufficient response to initial CyBorD induction could benefit from tailored pre-transplant intensification. At 100 days following autologous stem cell transplantation, the proportion of patients achieving a complete response or better was 9.5 percent across the entire enrolled cohort, failing to surpass the 20 percent benchmark previously documented in a historical trial using bortezomib and dexamethasone induction.

High-dose chemotherapy supported by autologous stem cell transplantation remains an established standard of care for transplant-eligible patients diagnosed with multiple myeloma, supported by demonstrable improvements in progression-free survival across prior clinical trials. Initial induction therapy widely employs triplet or quadruplet regimens combining dexamethasone with multiple novel anti-myeloma agents. However, escalating the number of concurrent induction agents can substantially elevate therapeutic toxicity and lead to potential overtreatment. In clinical practice, the management of patients who exhibit suboptimal or insufficient disease reduction following frontline induction regimens presents an ongoing challenge, as the specific therapeutic benefit of administering an adaptive second induction regimen prior to high-dose consolidation has remained poorly characterized in prospective settings.

To investigate the clinical utility of an individualized adaptation strategy, researchers initiated the PIANO study to determine whether adding lenalidomide and dexamethasone exclusively to patients failing to achieve at least a very good partial response after four standard cycles of CyBorD could rescue overall therapeutic efficacy. The intervention was evaluated against historical data from the collaborative TUBA study, which had assessed bortezomib and dexamethasone induction followed by autologous transplantation. A total of 64 patients were prospectively enrolled between March 2014 and December 2017, of whom one was subsequently deemed ineligible, leaving 63 evaluable participants aged 30 to 70 years with preserved major organ function and adequate performance status. The median age across the cohort was 60 years, and baseline staging indicated that 30.2 percent of patients presented with International Staging System stage I disease, 39.7 percent with stage II, and 30.2 percent with stage III.

The study protocol mandated that all participants begin with four cycles of initial CyBorD induction therapy, after which clinical response was systematically measured using serum and urinary monoclonal protein densitometry and serum free light chain assessments in accordance with International Myeloma Working Group response criteria. Under the trial design, individuals who achieved a very good partial response or better proceeded directly toward peripheral blood stem cell mobilization and transplantation. Conversely, patients who failed to achieve a very good partial response were assigned to receive up to four cycles of response-adapted intensification with lenalidomide and dexamethasone before moving to high-dose melphalan conditioning, autologous stem cell transplantation, and subsequent lenalidomide maintenance therapy scheduled for up to two years or until disease progression.

Across the entire cohort, four patients discontinued protocol therapy during initial CyBorD induction due to adverse events or investigator discretion. Among the remaining participants, 38 patients did not achieve a very good partial response after four CyBorD courses. Of these 38 patients, five discontinued treatment due to personal request or investigator decision, two proceeded directly to transplantation at the treating physician’s discretion, and 31 commenced lenalidomide and dexamethasone intensification. One additional participant whose response was initially classified as a partial response before later confirmation of very good partial response also received lenalidomide and dexamethasone, resulting in a total intensification cohort of 32 patients. Within this intensified subgroup, one individual discontinued therapy because of adverse events and one experienced disease progression, while 17 of the 32 patients demonstrated measurable improvement in response depth prior to proceeding toward transplant.

Peripheral blood stem cell collection was subsequently initiated in 48 patients, representing 76.2 percent of the evaluable study population. Mobilization regimens consisted of granulocyte colony-stimulating factor alone in 38 individuals and cyclophosphamide combined with granulocyte colony-stimulating factor in 13 patients, including three who underwent rescue mobilization after failing single-agent collection. Mobilization outcomes revealed similar success across treatment pathways, yielding a overall median cell yield of 2.51 times 10 to the sixth power CD34-positive cells per kilogram. Target cell doses determined by attending physicians were successfully obtained in 90 percent of patients who received CyBorD alone and in 93 percent of those who received additional lenalidomide and dexamethasone intensification, indicating that the interim immunomodulatory therapy did not impair subsequent stem cell procurement.

Ultimately, 44 patients underwent autologous stem cell transplantation with high-dose melphalan, achieving successful hematologic engraftment across all cases within a median duration of 12.5 days. Evaluation at day 100 post-transplantation confirmed that six patients achieved a complete response or better, representing 9.5 percent of the total 63 enrolled patients, with a 95 percent confidence interval spanning 3.6 percent to 19.6 percent. When restricted solely to the 44 patients who actually completed transplantation, the complete response or better rate reached 13.6 percent, with a 95 percent confidence interval of 5.2 percent to 27.4 percent. Within the specific subgroup of 32 patients who received lenalidomide and dexamethasone intensification, only a single individual achieved a complete response or better at the day 100 evaluation point.

Following transplantation and subsequent lenalidomide maintenance therapy, the best documented overall responses achieved were stringent complete response in 10 patients, complete response in one, very good partial response in 23, and partial response in eight, yielding an overall best complete response or better rate of 17.4 percent across the enrolled cohort. Over a median follow-up interval of 1,602 days, the three-year overall survival rate calculated from enrollment reached 90.0 percent, with a 95 percent confidence interval of 79.0 percent to 95.4 percent. The corresponding three-year progression-free survival rate stood at 43.9 percent, with a 95 percent confidence interval of 28.1 percent to 58.5 percent. Notably, survival comparisons demonstrated that post-transplant overall survival and progression-free survival trajectories were comparable between patients who received CyBorD alone and those who required additional intensification due to poor initial response.

Multivariate statistical analysis revealed that younger patient age was the sole baseline factor significantly associated with the attainment of very good partial response or better at 100 days following transplantation, exhibiting an odds ratio of 0.858. Conventional staging via the International Staging System did not demonstrate a significant association with response depth. In survival analyses, univariate testing identified Durie-Salmon stage III and high-risk cytogenetic abnormalities as factors associated with progression-free survival, although the predictive effect of cytogenetics retained only borderline statistical significance in multivariate modeling, with a hazard ratio of 2.311. Investigators noted that cytogenetic testing was assessable in 53 participants, among whom only nine harbored high-risk chromosomal lesions such as deletion 17p, translocation 4;14, or translocation 14;16.

Tolerability assessments documented 12 clinically meaningful protocol-related adverse events during the study period, including heart failure, hyperkalemia, and appetite loss during CyBorD; hyperglycemia and hypoxemia during lenalidomide and dexamethasone; and seven complications during maintenance therapy including pneumonia, pulmonary artery thrombosis, skin rash, hyperthyroidism, and three secondary primary malignancies comprising pancreatic, breast, and lymphoid cancers. Substantial treatment attrition occurred over the full therapeutic course, as only 39 patients initiated lenalidomide maintenance and only 15 completed the full planned 24-month duration. The investigators emphasized that while response-adapted lenalidomide intensification demonstrated feasibility and rescued pre-transplant depth in a subset of suboptimal responders, it failed to surpass historical complete response benchmarks, underscoring that current frontline practice has evolved toward contemporary quadruplet regimens incorporating anti-CD38 monoclonal antibodies.

Subject of Research: Response-adapted induction therapy outcomes in transplant-eligible multiple myeloma

Article Title: Response-adapted lenalidomide–dexamethasone (LenDex) intensification after CyBorD induction for transplant-eligible multiple myeloma: the PIANO study

Article References: Minakata, D., Yamamoto, G., Kako, S., Hiroshima, Y., Ota, S., Handa, T., Wake, A., Meguro, A., Usuki, K., Tsukada, N., Nakasone, H., & Kanda, Y. (2026). Response-adapted lenalidomide–dexamethasone (LenDex) intensification after CyBorD induction for transplant-eligible multiple myeloma: the PIANO study. Blood Research, 61(1), Article 37. https://doi.org/10.1007/s44313-026-00154-1

Image Credits: AI Generated

DOI: 10.1007/s44313-026-00154-1

Keywords: multiple myeloma, clinical trials, oncology, chemotherapy, stem cell transplantation, lenalidomide, CyBorD, hematology, Response-adapted, dexamethasone, LenDex, intensification

News Source: Nathaniel Bowman. (November 8, 2026). Adaptive Lenalidomide Intensification Evaluated Following CyBorD Induction in Multiple Myeloma. Scienmag.

Tags: chemotherapyClinical TrialsCyBorDdexamethasoneHematologyintensificationlenalidomideLenDexmultiple myelomaOncologyResponse-adaptedstem cell transplantation
Share12Tweet7Share2ShareShareShare1

Related Posts

Nitrate and Sialin Protect Masseter Muscle by Preserving Mitochondrial Homeostasis in Mice

Nitrate and Sialin Protect Masseter Muscle by Preserving Mitochondrial Homeostasis in Mice

November 20, 2026
Albumin Infusions Manage Cirrhosis Fluid Buildup When Tailored to Patient Needs

Albumin Infusions Manage Cirrhosis Fluid Buildup When Tailored to Patient Needs

November 20, 2026

Cadaver Study Clarifies Endopelvic Fascia Continuity in Rectal Anatomy

November 20, 2026

Paraspinal Muscle Degeneration Correlates With Postoperative Outcomes in Lumbar Spinal Stenosis

November 20, 2026

POPULAR NEWS

  • Pressurized Isopropanol Extracts Antioxidants and Enzyme Inhibitors From Prickly Pear Seeds

    Pressurized Isopropanol Extracts Antioxidants and Enzyme Inhibitors From Prickly Pear Seeds

    29 shares
    Share 12 Tweet 7
  • Integrated Photonic Quantum Converter Enhances Digital Phase Estimation in Metrology

    29 shares
    Share 12 Tweet 7
  • Endoscopic Ultrasound Expands Diagnostic and Guided Interventional Roles in Pancreatic Disease

    29 shares
    Share 12 Tweet 7
  • Full-Length TDP-43 Protein Propagates From Motor Cortex to Muscle in Rats

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Nitrate and Sialin Protect Masseter Muscle by Preserving Mitochondrial Homeostasis in Mice

Albumin Infusions Manage Cirrhosis Fluid Buildup When Tailored to Patient Needs

Cadaver Study Clarifies Endopelvic Fascia Continuity in Rectal Anatomy

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 89 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.